Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis DS or DS mosaicism by karyotype or chromosomal analysis~* Diagnosis of myelodysplastic syndromes (MDS) with \< 30% blasts or acute myeloid leukemia (AML)~  * Newly diagnosed disease~* Patients with a history of transient myeloproliferative disorder (TMD) are eligible provided the patient is diagnosed with AML or MDS at \> 90 days of age AND meets either of the following criteria:~  * At least 30% blasts in the bone marrow regardless of time since resolution of TMD~ * More than 8 weeks since resolution of TMD with ≥ 5% blasts in the bone marrow~* Immunophenotype required for study entry~* No promyelocytic leukemia~* Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by radionuclide angiogram~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST or ALT \< 2.5 times ULN~* Creatinine adjusted according to age as follows:~  * No greater than 0.4 mg/dL (≤ 5 months)~ * No greater than 0.5 mg/dL (6 months -11 months)~ * No greater than 0.6 mg/dL (1 year-23 months)~ * No greater than 0.8 mg/dL (2 years-5 years)~ * No greater than 1.0 mg/dL (6 years-9 years)~ * No greater than 1.2 mg/dL (10 years-12 years)~ * No greater than 1.4 mg/dL (13 years and over \[female\])~ * No greater than 1.5 mg/dL (13 years to 15 years \[male\])~ * No greater than 1.7 mg/dL (16 years and over \[male\])~* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min~* No evidence of dyspnea at rest~* No exercise intolerance~* Pulse oximetry \> 94%~* No prior chemotherapy, radiotherapy, or any antileukemic therapy~  * Intrathecal cytarabine therapy given at diagnosis allowed~* Prior therapy for TMD allowed

- Gender: ALL
- Minimum Age: None
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (combination chemotherapy) (Type: EXPERIMENTAL): INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV continuously, and oral thioguanine BID on days 1-4. COURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1, 2, 8, and 9 and asparaginase (IM) on days 2 and 9.~COURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV, daunorubicin hydrochloride IV, and oral thioguanine as in course I~INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).